Kiri
| Dokumendiregister | Terviseamet |
| Viit | 11.2-1/24/7775-1 |
| Registreeritud | 30.07.2024 |
| Sünkroonitud | 31.07.2024 |
| Liik | Sissetulev dokument |
| Funktsioon | 11.2 Turustamise eelne järelevalve (pre-marketing surveillance) |
| Sari | 11.2-1 Meditsiiniseadmete kliiniliste uuringute ja toimivusuuringute dokumendid (taotlused, load, muud teavitused ja kirjavahetus) |
| Toimik | 11.2-1/2024 |
| Juurdepääsupiirang | Avalik |
| Juurdepääsupiirang | |
| Adressaat | IQVIA MedTech |
| Saabumis/saatmisviis | IQVIA MedTech |
| Vastutaja | Merili Saar-Abroi (TA, Peadirektori asetäitja (1) vastutusvaldkond, Meditsiiniseadmete osakond) |
| Originaal | Ava uues aknas |
Failid
From: "Podolak, Amira" <[email protected]>
Sent: Tue, 23 Jul 2024 10:16:30 +0000
To: "[email protected]" <[email protected]>
Cc: "Mukhopadhyay; Rupsha" <[email protected]>
Subject: End of study
Dear Health Board Team,
Could you please tell me what is required for study completion information? Is an email notification sufficient or cover letter will be required? Also, will there be any AoR once end of study is submitted?
I would appreciate your response on this matter.
Kind regards,
Amira Podolak, Ph.D.
Sr. Regulatory & Start-Up Specialist
IQVIA MedTech, Clinical Operations
Learn more about IQVIA MedTech
Home Based (Gdynia, Poland)
tel. +48 22 430 31 34
Upcoming ooo: 05-16Aug (both included)
________________________________________
IMPORTANT - PLEASE READ: This electronic message, including its attachments, is CONFIDENTIAL and may contain PROPRIETARY or LEGALLY PRIVILEGED or PROTECTED information and is intended for the authorized recipient of the sender. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution of this message or any of the information included in it is unauthorized and strictly prohibited. If you have received this message in error, please immediately notify the sender by reply e-mail and permanently delete this message and its attachments, along with any copies thereof, from all locations received (e.g., computer, mobile device, etc.). To the extent permitted by law, we may monitor electronic communications for the purposes of ensuring compliance with our legal and regulatory obligations and internal policies. We may also collect email traffic headers for analyzing patterns of network traffic and managing client relationships. For further information see our privacy-policy. Thank you.
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Seosed
| Nimi | K.p. | Δ | Viit | Tüüp | Org | Osapooled |
|---|---|---|---|---|---|---|
| Vastuskiri | 30.07.2024 | 1 | 11.2-1/24/7775-2 | Väljaminev dokument | ta | IQVIA MedTech |